



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/772,938	01/31/2001	Nabil Hanna	P 0276658 1992-30-0466CP	9882
7590	12/01/2003		EXAMINER	
PILLSBURY WINTHROP LLP 11682 EL CAMINO REAL SUITE 200 SAN DIEGO, CA 92130			GAMBEL, PHILLIP	
			ART UNIT	PAPER NUMBER
			1644	
				18
				DATE MAILED: 12/01/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	0A17729381 GAMBLE	HAROLD A. 1644
-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -- Period for Reply		
<p>A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.</p> <ul style="list-style-type: none"> - Extensions of time may be available under the provisions of 37 CFR 1.138(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 		
Status <p>1)<input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>10/8/03</u></p> <p>2a)<input type="checkbox"/> This action is FINAL. 2b)<input checked="" type="checkbox"/> This action is non-final.</p> <p>3)<input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11, 453 O.G. 213.</p>		
Disposition of Claims <p>4)<input checked="" type="checkbox"/> Claim(s) _____ is/are pending in the application. <u>1,513,16-17, 19-27</u></p> <p>4a) Of the above claim(s) _____ is/are withdrawn from consideration.</p> <p>5)<input type="checkbox"/> Claim(s) _____ is/are allowed.</p> <p>6)<input checked="" type="checkbox"/> Claim(s) _____ is/are rejected. <u>1,513,16-17, 19-27</u></p> <p>7)<input type="checkbox"/> Claim(s) _____ is/are objected to.</p> <p>8)<input type="checkbox"/> Claim(s) _____ are subject to restriction and/or election requirement.</p>		
Application Papers <p>9)<input type="checkbox"/> The specification is objected to by the Examiner.</p> <p>10)<input type="checkbox"/> The drawing(s) filed on _____ is/are: a)<input type="checkbox"/> accepted or b)<input type="checkbox"/> objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).</p> <p>11)<input type="checkbox"/> The proposed drawing correction filed on _____ is: a)<input type="checkbox"/> approved b)<input type="checkbox"/> disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.</p> <p>12)<input type="checkbox"/> The oath or declaration is objected to by the Examiner.</p>		
Priority under 35 U.S.C. §§ 119 and 120 <p>13)<input type="checkbox"/> Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)<input type="checkbox"/> All b)<input type="checkbox"/> Some * c)<input type="checkbox"/> None of: 1.<input type="checkbox"/> Certified copies of the priority documents have been received. 2.<input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____. 3.<input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.</p> <p>14)<input type="checkbox"/> Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application). a)<input type="checkbox"/> The translation of the foreign language provisional application has been received.</p> <p>15)<input checked="" type="checkbox"/> Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</p>		
Attachment(s) <p>1)<input checked="" type="checkbox"/> Notice of References Cited (PTO-892) 2)<input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) 3)<input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____</p> <p>4)<input type="checkbox"/> Interview Summary (PTO-413) Paper No(s) _____. 5)<input type="checkbox"/> Notice of Informal Patent Application (PTO-152) 6)<input type="checkbox"/> Other: _____</p>		

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114; and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office Action has been withdrawn pursuant to 37 CFR 1.114.

Applicant's submission filed on 10/8/03 has been entered.

Applicant's Request for Reconsideration, filed 10/8/03, has been entered.

Claims 1, 5-13, 16-17 and 19-27 are pending and being acted upon presently.

Claims 2-4, 14-15, 18 and 42-56 have been canceled previously.

2. The text of those sections of Title 35 USC not included in this Action can be found in a prior Action.

This Office Action will be in response to applicant's arguments, filed 10/8/03

The rejections of record can be found in the previous Office Actions.

Applicant's arguments and the examiner's rebuttal are essentially the same of record.

3. Claims 1, 5-13, 16-17 and 19-27 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Kaminski et al. (U.S. Patent No. 6,287,537) AND/OR Anderson et al. (U.S. Patent No. 5,843,439) in view of Gruss et al. (Leukemia and Lymphoma 24: 393-422, 1997), Carbone et al. (Am. J. Pathol. 147: 912-922, 1995), Black et al. (U.S. Patent No. 6,001,358), in view of standard chemotherapeutic treatments, including combination therapy of malignancies, including lymphomas known and practiced by the ordinary artisan at the time the invention was made, as acknowledged on pages 41-45 of the instant specification essentially for the reasons of record set forth in the previous Office Actions.

Applicant's arguments, filed 10/8/03, have been fully considered but are not found convincing essentially for the reasons of record and addressed herein.

Applicant's arguments and the examiner's rebuttal are essentially the same of record.

Applicant asserts in conjunction with a number of legal citations that the cited references lack a specific suggestion or motivation to perform the claimed combination.

Applicant argues that the prior art identify a combination therapy not presently claimed and that the prior art lack a specific suggestion or motivation to combine anti-CD20 therapy with anti-CD40L treatment. Applicant notes that neither Anderson nor Kaminsk specifically suggest or motivate combination of anti-CD20 antibody with anti-CD40L therapy, as currently claimed.

Applicant argues that Gruss, Carbone and Black do not cure the deficiencies of Kaminski and/or Anderson as they similarly fail to specifically suggest or motivate the invention now claimed. Applicant argues that Gruss, Carbone and Black describe the role of CD40/CD40L signaling in lymphoma progression and management, but lack any reference to treatment methods that include anti-CD20 therapy.

Again, applicant asserts the claimed methods produce unexpected results. Applicant submits that the claimed invention relies upon the unexpected discovery that administration of an antibody that antagonizes the interaction of CD40 and CD40L unexpectedly and synergistically enhances the anti-lymphoma activity of an anti-CD20 antibody. Applicant has further asserted that at the time the invention was filed that it was not known that the combination of these two antibodies would interact synergistically to kill lymphoma cells. Applicant has relied upon the results set forth in the instant Figure 2b, Table I of Example 3 for the increased cytotoxicity and apoptosis of B lymphoma cells with the combination of anti-CD20 antibodies and blocking interaction between CD40 and CD40L.

Contrary to the assertion of the examiner's position of record, applicant asserts that the disclosed synergistic effects are inconsistent with a sum of the therapeutic effects of anti-CD20 and anti-CD40L antibodies when administered individually and that the more durable and potent clinical response, as now observed when anti-CD20 and anti-CD40L therapies are combined was unpredicted prior to the disclosure of the instant application.

However, there does not appear to objective evidence to support applicant's assertions of a more durable and potent clinical response. Applicant is invited to provide such objective evidence to support the arguments of counsel.

As pointed out previously, Kaminski et al. teach the use of anti-CD20 antibodies, including radiolabeled anti-CD20 antibodies (e.g. B1) in combination with other treatments to treat B cell malignancies, including non-Hodgkin's lymphoma (e.g. column 8, paragraph 1) (see entire document, Summary of the Invention and Detailed Description of the Invention). Kaminski et al. teach various modes of dosages and administration that were well known to those of skill in the art in the treatment of B cell malignancy (e.g. see columns 9-12 and Examples), encompassed by the claimed invention.

Also, Anderson et al. teach the use of anti-CD20, including radiolabeled anti-CD20 antibodies (e.g. 2B8) in cooperative strategies to treat B cell malignancies, including non-Hodgkin's lymphoma (e.g. column 3, paragraph 2) (See entire document, including Background of the Invention, Summary of the Invention, Detailed Description of the Invention, Claims).

Again, therefore in contrast to applicant's assertions, the prior art taught combination therapy to various B cell malignancies, including B cell non-Hodgkin's lymphoma with CD20-specific antibodies at the time the invention was made. Providing radiotherapy and chemotherapy was known and routinely practiced at the time the invention was made in the treatment of non-Hodgkin's lymphomas at the time the invention was made.

As pointed out previously and in contrast to applicant's assertions of unexpected synergistic results, the following is noted. The role of the anti-CD20 antibody and the blocking the interaction between CD40 and CD40L in treating B cell malignancy differ. Here, the prior art of Carbone et al. and Gruss et al. taught the importance of CD40L-mediated interactions in B cell non-Hodgkin's lymphoma and clinical manifestations of lymphoma growth and therapeutic intervention. Also as pointed out above, Gruss et al. does teach that CD40:CD40L interactions are part of cellular activation and neoplastic tumor cell growth which would be useful for the therapeutic management of CD40⁺ tumors (see page 404, column 1). Further, applicant appears to rely upon certain experimental conditions with certain cell lines to support their assertions of unexpected results. However, these results do not appear to be inconsistent with the expected roles of blocking CD40 interaction with CD40L and targeting CD20 in the treatment of B cell malignancy, including B cell non-Hodgkin's lymphoma, taught by the combination of references in the prior art.

As pointed out previously, Carbone et al. teach the expression of CD40 on B cell non-Hodgkin's lymphoma and CD40 ligand expressing cells T cells were detected within neoplastic follicles and surrounding areas via immunohistochemistry analysis (see entire document, particularly page 917; B-Cell NHL). Carbone et al. also discuss the role such CD40 ligand expressing T cells on CD40 expressing B cell lymphoma proliferation (See Discussion, particularly page 920, column 1, paragraph 1).

Also, Gruss et al. teach that CD40 is expressed on B cell lymphomas and that the CD40:CD40L pathway, including CD40L-expressing T cells, which are readily detectable around neoplastic B cells, enhance B cell activation and growth (see pages 404-405, B cell Lymphomas and Lymphoproliferative Disorders and Discussion). Gruss et al. teach that the anti-proliferative and pro-apoptotic effects of recombinant CD40L on high grade B-NHLs offer an appealing biologic approach for treatment of these neoplasms (page 405, column 1). While Gruss et al. disclose the art known formation of neutralizing anti-mouse antibodies as a limitation of antibody therapy (page 405, column 1, lines 24-27), such limitations have been long addressed by the use of recombinant antibodies such as humanized antibodies, known and practiced in the art for a decade (also, see Black et al. herein).

Therefore, the role of anti-proliferative and pro-apoptotic effects of targeting CD40L on high grade B-NHLs offered an approach for treatment of these neoplasms was taught and known by the prior art teachings. It would have been expected that targeting CD40L on high grade B-NHLs would have left such cells more sensitive to treatment with anti-CD20 antibodies. Again, given the expression of CD20 and CD40 and the ability of activation via CD20 and/or CD40, the ordinary artisan would have been motivated to target B cell non-Hodgkin's lymphoma directly with radiolabeled CD20-specific antibodies and to diminish activation of said B cell leukemia by blocking activation by CD40 ligand expressing T cells with CD40L-specific antibodies.

Given the teachings of Kaminski et al. to employ radiolabeled antibodies in combination with other treatments to treat leukemia as well as the acknowledgment by applicant that combination therapy was known and practiced in the art at the time the invention was made, one of ordinary skill in the art would have been motivated to treat B cell leukemia with a combination of therapies.

Given the expression of CD20 and CD40 and the ability of activation via CD20 and/or CD40, the ordinary artisan would have been motivated to target B cell non-Hodgkin's lymphoma directly with radiolabeled CD20-specific antibodies and to diminish activation of said B cell leukemia by blocking activation by CD40 ligand expressing T cells with CD40L-specific antibodies.

One of ordinary skill in the art would have employed non-radiolabeled CD40L-specific antibodies, given the expression of CD40L on normal activated T cells and the role of such CD40L on such T cells to stimulate CD40-expressing B cell lymphoma cells, as taught above.

Given the standard regimen of chemotherapy in leukemic patients and the teachings of Kaminski et al. to combine standard therapy with radiolabeled antibodies, one of ordinary skill in the art at the time the invention was made to employ multiple modalities to treat B cell lymphomas. Given the addition of non-radiolabeled CD40L-specific antibodies, the ordinary artisan would have been administering a less toxic therapeutic regimen, when compared to radiolabeled antibodies and chemotherapeutic agents.

One of ordinary skill in the art at the time the invention was made would have been motivated to select radiolabeled CD20-specific antibodies, non-radiolabeled CD40L-specific antibodies and standard chemotherapeutic to treat B cell lymphomas at the time the invention was made, given the teachings above. From the teachings of the references, it was apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Applicant's arguments are not found persuasive.

As pointed out previously, for the record, it is apparent that IDEC-C2B8 and Mab 24-31 antibodies are required to practice the claimed invention. As required elements, they must be known and readily available to the public or obtainable by a repeatable method set forth in the specification. If they are not so obtainable or available, the enablement requirements of 35 USC 112, first paragraph, may be satisfied by a deposit of the pertinent cell lines / hybridomas which produce these antibodies. See 37 CFR 1.801-1.809.

Given the disclosure and the claims encompassing the instant IDEC-C2B8 and Mab 24-31 antibodies set forth in the claims of U.S. Patent Nos. 5,843,439 and 6,001,358.; the conditions for the deposit of biological materials under 35 USC 112, first paragraph, with respect to IDEC-C2B8 and Mab 24-31 appear to have been satisfied.

If applicant intends that IDEC-C2B8 and Mab 24-31 antibodies refer to antibodies other than that encompassed by the exact limitations of these patented claims, then the instant claims would be subject to a rejection under 35 USC 112, first paragraph, for the deposit of biological materials.

4. Claims 1, 5-13, 16-17 and 19-27 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over pending claims of copending application USSNs 09/435,992 and 09/855,717.

Given the election in the instant case, the conflicting claims may or may not be identical, depending upon the invention(s) elected in these copending applications. The claims are not patentably distinct from each other because they appear to read on the same or nearly the same reagents to treat the same or nearly the same leukemias and lymphomas.

This is a *provisional* obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicant's amendment, filed 10/8/03, indicates that a terminal disclaimer will be filed with respect to copending USSN 09/435,992.

Again, applicant is invited to clarify whether treating lymphoma and leukemia are patentably distinct. For example, applicant's election in Paper No. 6 indicated that the examiner would broaden the search and examination to all B cell lymphomas and leukemias.

5. No claim is allowed.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (703) 308-3997. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

After January 20, 2004, Phillip Gambel's telephone number will be (571) 272-0844 and
Christina Chan's telephone Number will be (571) 272-0841.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 972-9306.

Phillip Gambel
Phillip Gambel, PhD.
Primary Examiner
Technology Center 1600
December 1, 2003